Literature DB >> 17555476

Prognostic significance of p27Kip1 expression in bladder cancer.

Farhang Rabbani1, Theresa M Koppie, Elizabeth Charytonowicz, Marija Drobnjak, Bernard H Bochner, Carlos Cordon-Cardo.   

Abstract

UNLABELLED: The importance of markers in urological cancer is well recognised and many attempts are being made to find one which will be of prognostic significance. Authors from New York found that low expression of p27Kip1 in patients with bladder cancer was a significant predictor of pelvic recurrence, progression to metastasis and death. Authors from Switzerland examined patients with a primary solitary distal ureteric TCC; they found that distal ureteric resection in such patients is feasible, and that the long-term oncological outcome appears to be comparable to more radical treatment of this condition.
OBJECTIVE: To define the prognostic significance of p27(Kip1) expression in bladder cancer for overall, disease-specific, metastasis-free and pelvic recurrence-free survival, and to identify clinical and pathological correlates of p27(Kip1) immunophenotypes. PATIENTS AND METHODS: Tumour samples from 128 evaluable patients with bladder cancer were assessed by immunohistochemistry for p27(Kip1) and E2F-1 expression. Immunoreactivity of p27(Kip1) was correlated with clinicopathological variables, E2F-1 immunoreactivity, and outcome. Multivariate analysis was used to assess predictors of outcome. The median follow-up was 30.9 months overall and 105.7 months in the 32 patients alive at the last follow-up.
RESULTS: The fraction of tumour cells with p27(Kip1) nuclear immunoreactivity was <5% in 15, 5-25% in 30, 25-50% in 19, 50-75% in 51, and > or = 75% in 13 patients. High-grade tumours and those with lower E2F-1 nuclear reactivity had a lower mean percentage p27(Kip1) reactivity (P = 0.047 and 0.011, respectively). On multivariate analysis, the percentage p27(Kip1) reactivity was a significant independent predictor of pelvic recurrence (P = 0.017), progression to metastases (P = 0.046), death from disease (P = 0.008), and death from any cause (P = 0.017), with a low expression portending a worse prognosis. Suspicion of vascular invasion was a significant independent predictor of progression to metastases (P = 0.002), death from disease, and death from any cause (both P < 0.001). Lymph node involvement was a significant independent predictor of progression to metastases (P = 0.006).
CONCLUSIONS: Low expression of p27(Kip1) was a significant independent predictor of pelvic recurrence, progression to metastasis, death from disease and death from any cause, in patients with bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555476     DOI: 10.1111/j.1464-410X.2007.06927.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

1.  [Molecular markers in the diagnostics and therapy of urothelial cancer].

Authors:  C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2010-11       Impact factor: 0.639

2.  AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27.

Authors:  Stavros Kopsiaftis; Katie L Sullivan; Isha Garg; John A Taylor; Kevin P Claffey
Journal:  Mol Cancer Res       Date:  2016-09-16       Impact factor: 5.852

3.  Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.

Authors:  Kyungeun Kim; Yong Mee Cho; Bong-Hee Park; Jae-Lyun Lee; Jae Y Ro; Heounjeong Go; Jung Weon Shim
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 4.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 5.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

6.  Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.

Authors:  Yu-Feng Tian; Hui-Ching Wang; Chi-Wen Luo; Wen-Chun Hung; Yu-Han Lin; Tzu-Yi Chen; Chien-Feng Li; Chen-Yi Lin; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

7.  Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Authors:  Luciana Schultz; Roula Albadine; Jessica Hicks; Sana Jadallah; Angelo M DeMarzo; Ying-Bei Chen; Matthew E Nielsen; Matthew E Neilsen; Mark L Gonzalgo; David Sidransky; Mark Schoenberg; George J Netto
Journal:  Cancer       Date:  2010-10-11       Impact factor: 6.860

8.  Late age (85 years or older) peak incidence of bladder cancer.

Authors:  Matthew Schultzel; Sidney L Saltzstein; Tracy M Downs; Suzuho Shimasaki; Catherine Sanders; Georgia Robins Sadler
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

9.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

10.  High-throughput screening reveals alsterpaullone, 2-cyanoethyl as a potent p27Kip1 transcriptional inhibitor.

Authors:  Brandon J Walters; Wenwei Lin; Shiyong Diao; Mark Brimble; Luigi I Iconaru; Jennifer Dearman; Asli Goktug; Taosheng Chen; Jian Zuo
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.